BACKGROUND: High white blood cell count at presentation is an unfavorable prognostic factor for treatment outcome in intermediate cytogenetic risk acute myeloid leukemia. Since the impact of white blood cell count on outcome of subgroups defined by the molecular markers NPMc(+) and FLT3-internal tandem duplication (ITD) is unknown, we addressed this issue. DESIGN AND METHODS: We studied the effect of white blood cell count on outcome in a clinically and molecularly well-defined cohort of 525 patients with acute myeloid leukemia using these molecular markers. In addition, since an increased white blood cell count has been associated with an increased FLT3-ITD/FLT3 (wild-type) ratio, we investigated whether the effect of white blood cell count on outcome could be explained by the FLT3-ITD/FLT3 ratio. RESULTS: This analysis revealed that white blood cell count had no impact on outcome in patients with the genotypic combinations 'NPMc(+) without FLT3-ITD' and 'NPM1 wild-type with or without FLT3-ITD'. In contrast, white blood cell count had a significant impact on complete remission rate (P=0.034), event-free survival (P=0.009) and overall survival (P<0.001) in patients with the genotypic combination 'NPMc(+) with FLT3-ITD'. A FLT3-ITD/FLT3 ratio greater than 1 was also associated with a reduced complete remission rate (P=0.066) and significantly reduced event-free survival (P= 0.001) and overall survival (P=0.001) in patients with the genotypic combination 'NPMc(+) with FLT3-ITD'. Multivariable analysis revealed that white blood cell count and FLT3-ITD/FLT3 ratio were independent prognostic indicators for outcome in the subgroup with the genotypic combination 'NPMc(+) with FLT3-ITD'. CONCLUSIONS: Our results demonstrate that both high white blood cell count and FLT3-ITD/FLT3 ratio are prognostic factors in patients with acute myeloid leukemia with the genotypic combination 'NPMc(+) with FLT3-ITD'.
BACKGROUND: High white blood cell count at presentation is an unfavorable prognostic factor for treatment outcome in intermediate cytogenetic risk acute myeloid leukemia. Since the impact of white blood cell count on outcome of subgroups defined by the molecular markers NPMc(+) and FLT3-internal tandem duplication (ITD) is unknown, we addressed this issue. DESIGN AND METHODS: We studied the effect of white blood cell count on outcome in a clinically and molecularly well-defined cohort of 525 patients with acute myeloid leukemia using these molecular markers. In addition, since an increased white blood cell count has been associated with an increased FLT3-ITD/FLT3 (wild-type) ratio, we investigated whether the effect of white blood cell count on outcome could be explained by the FLT3-ITD/FLT3 ratio. RESULTS: This analysis revealed that white blood cell count had no impact on outcome in patients with the genotypic combinations 'NPMc(+) without FLT3-ITD' and 'NPM1 wild-type with or without FLT3-ITD'. In contrast, white blood cell count had a significant impact on complete remission rate (P=0.034), event-free survival (P=0.009) and overall survival (P<0.001) in patients with the genotypic combination 'NPMc(+) with FLT3-ITD'. A FLT3-ITD/FLT3 ratio greater than 1 was also associated with a reduced complete remission rate (P=0.066) and significantly reduced event-free survival (P= 0.001) and overall survival (P=0.001) in patients with the genotypic combination 'NPMc(+) with FLT3-ITD'. Multivariable analysis revealed that white blood cell count and FLT3-ITD/FLT3 ratio were independent prognostic indicators for outcome in the subgroup with the genotypic combination 'NPMc(+) with FLT3-ITD'. CONCLUSIONS: Our results demonstrate that both high white blood cell count and FLT3-ITD/FLT3 ratio are prognostic factors in patients with acute myeloid leukemia with the genotypic combination 'NPMc(+) with FLT3-ITD'.
Authors: Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: S P Whitman; K J Archer; L Feng; C Baldus; B Becknell; B D Carlson; A J Carroll; K Mrózek; J W Vardiman; S L George; J E Kolitz; R A Larson; C D Bloomfield; M A Caligiuri Journal: Cancer Res Date: 2001-10-01 Impact factor: 12.701
Authors: Gert J Ossenkoppele; Wilfried J Graveland; Pieter Sonneveld; Simon M G J Daenen; Douwe H Biesma; Leo F Verdonck; M Ron Schaafsma; Petra H M Westveer; Godefridus J Peters; Paul Noordhuis; Petra Muus; Dominik Selleslag; Bronnie van der Holt; Michel Delforge; Bob Löwenberg; Gregor E G Verhoef Journal: Blood Date: 2003-12-04 Impact factor: 22.113
Authors: Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch Journal: Blood Date: 2007-10-23 Impact factor: 22.113
Authors: Bob Löwenberg; Wim van Putten; Matthias Theobald; Jurg Gmür; Leo Verdonck; Pieter Sonneveld; Martin Fey; Harry Schouten; Georgine de Greef; Augustin Ferrant; Tibor Kovacsovics; Alois Gratwohl; Simon Daenen; Peter Huijgens; Marc Boogaerts Journal: N Engl J Med Date: 2003-08-21 Impact factor: 91.245
Authors: John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: J Versluis; F E M In 't Hout; R Devillier; W L J van Putten; M G Manz; M-C Vekemans; M-C Legdeur; J R Passweg; J Maertens; J Kuball; B J Biemond; P J M Valk; B A van der Reijden; G Meloni; H C Schouten; E Vellenga; T Pabst; R Willemze; B Löwenberg; G Ossenkoppele; F Baron; G Huls; J J Cornelissen Journal: Leukemia Date: 2016-06-24 Impact factor: 11.528
Authors: Antonella Caivano; Francesco La Rocca; Vittorio Simeon; Marco Girasole; Simone Dinarelli; Ilaria Laurenzana; Angelo De Stradis; Luciana De Luca; Stefania Trino; Antonio Traficante; Giovanni D'Arena; Giovanna Mansueto; Oreste Villani; Giuseppe Pietrantuono; Luca Laurenti; Luigi Del Vecchio; Pellegrino Musto Journal: Cell Oncol (Dordr) Date: 2016-10-19 Impact factor: 6.730
Authors: Samantha M Tracy; Carolina L Z Vieira; Eric Garshick; Veronica A Wang; Barrak Alahmad; Ryan Eid; Joel Schwartz; Jessica E Schiff; Pantel Vokonas; Petros Koutrakis Journal: Environ Res Date: 2021-09-17 Impact factor: 6.498
Authors: Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J Jusko Journal: Cancer Chemother Pharmacol Date: 2020-08-03 Impact factor: 3.333
Authors: Celalettin Ustun; Elizabeth A Morgan; Ethan M Ritz; Hanne Vestergaard; Sheeja Pullarkat; Philip M Kluin; Robert Ohgami; Linda B Baughn; Young Kim; Nam K Ku; David Czuchlewski; Michael Boe Møller; Ana-Iris Schiefer; Krzysztof Mrózek; Hans-Peter Horny; Tracy I George; Thomas Kielsgaard Kristensen; Todd Beck; Sunita Nathan; Cecilia Arana Yi; Cecilia Yeung; Vinod Pullarkat; Jason Gotlib; Cem Akin; Jessica Kohlschmidt; Amandeep Salhotra; Lori Soma; Dong Chen; Se Y Han; Christina Cho; Wolfgang Sperr; Sigurd Broesby-Olsen; Michael A Linden; Michelle Dolan; Gregor Hoermann; Jason L Hornick; Clara Bloomfield; Ryo Nakamura; H Joachim Deeg; Mark R Litzow; Gautam Borthakur; Daniel Weisdorf; Gerwin Huls; Miguel-Angel Perales; Peter Valent; Guido Marcucci Journal: Int J Lab Hematol Date: 2020-09-14 Impact factor: 2.877
Authors: Suruchi Pacharne; Oliver M Dovey; Jonathan L Cooper; Muxin Gu; Mathias J Friedrich; Sandeep S Rajan; Maxim Barenboim; Grace Collord; M S Vijayabaskar; Hannes Ponstingl; Etienne De Braekeleer; Ruben Bautista; Milena Mazan; Roland Rad; Konstantinos Tzelepis; Penny Wright; Malgorzata Gozdecka; George S Vassiliou Journal: Blood Adv Date: 2021-05-11